ECOG Pathology Coordination Office - Reference Laboratory: E2208 Randomized Phase II Study of Paclitaxel with or without the Anti-IGF-IR nAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients with Metastatic Esophageal or GE Junction Cancer

Project: Research project

Project Details

StatusFinished
Effective start/end date9/21/10 → 9/20/14

Funding

  • Frontier Science and Technology Research Foundation (PCOE2208-00)
  • ImClone Systems Incorporated (PCOE2208-00)